Stemline's synthetic multi-peptide cancer vaccine enters Phase 2.
Eva M
EM
Riedmann
D001932:Brain Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D016896:Treatment Outcome; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D019496:Cancer Vaccines; D022223:Vaccines, Subunit